key: cord-0909004-5tpkcd5z
authors: Phetsouphanh, C.; Darley, D.; Howe, A.; Munier, C. M. L.; Patel, S. K.; Juno, J. A.; Burrell, L. M.; Kent, S. J.; Dore, G. J.; Kelleher, A. D.; Matthews, G.
title: Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection
date: 2021-06-03
journal: nan
DOI: 10.1101/2021.06.01.21257759
sha: 43390013c87fa8429e0c916bf6e6f5d30e0e2629
doc_id: 909004
cord_uid: 5tpkcd5z

A proportion of patients surviving acute COVID-19 infection develop post-COVID syndrome (long COVID) encompassing physical and neuropsychiatric symptoms lasting longer than 12 weeks. Here we studied a prospective cohort of individuals with long COVID (the ADAPT study) compared to age/gender matched subjects without long COVID, healthy donors and individuals infected with other non-SARS CoV2 human coronaviruses (the ADAPT-C study). We found an elevated diffuse serum inflammatory cytokine profile in symptomatic long COVID subjects that was maintained at 8 months post-infection and was not observed in asymptomatic COVID-19 survivors. This inflammatory profile consisted of 15 cytokines that positively correlated; revealing an apparent diffuse, potentially coordinated, low level up regulation of a spectrum of immune and inflammatory mediators. In addition, we found an absence of subsets of un-activated naive T and B cells in peripheral blood of long COVID subjects, that did not reconstitute over time. In contrast, individual serum cytokines from the interferon I and III classes, T cell activation markers and plasma ACE2, while elevated in the serum of people previously infected with SARS-CoV-2 were not further elevated in subjects with long COVID symptoms. This work defines immunological parameters associated with long COVID and suggests future opportunities to prevention and treatment.

Coronavirus disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterised by a wide spectrum of clinical severities in the acute phase, ranging from asymptomatic to severe fatal forms 1,2 .

Immunological disturbance during acute illness has been well described and is likely to both play a role in host defence and be involved in the pathogenesis of severe COVID-19 3 , as evidenced by occurrences of systemic inflammatory syndromes of haemophagocytic lymphohistiocyosis (HLH) and cytokine release syndrome (CRS) 4,5 . Immunological abnormalities described in the acute phase include significant immune dysregulation with lymphopaenia and elevations in IL-2, IL-6, TGF-b, IL-10, GM-CSF and TNF 3, 6 .

A proportion of patients surviving acute COVID-19 develop post-COVID syndrome encompassing various physical and neuropsychiatric symptoms lasting longer than 12 weeks, also known as chronic COVID syndrome (CCS), post-acute sequelae of COVID-19 (PASC) and long-haul COVID (long COVID) [7] [8] [9] [10] . Although well described following other viral infections including Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1) [11] [12] [13] and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) 14 , these syndromes appear commonly following SARS-CoV-2 infection including following initial mild-moderate illness 15-18 . Persistent symptoms 6 months after hospitalization were observed in 76% of discharged patients in a study by Huang et al, with the most frequent symptoms reported being muscle weakness and fatigue 19, 20 . Amongst community managed COVID-19 cases, prevalence of persisting symptoms is lower, but remains higher than might be expected given the severity of the intial illness, affecting between 10-30% of individuals at 2-3 months post infection, 21, 22 continuing out to at least 8 months after initial illness 23 .

The spectrum of post-acute sequelae of COVID-19 (henceforth denoted as long COVID) is broad encompassing as many as 50 plus symptoms (long COVID meta-analysis) although characteristically manifests as severe relapsing fatigue often accompanied by dyspnoea, chest tightness, cough and headache 24 . The underlying pathophysiology of long COVID is poorly understood and there is currently little evidence defining the mechanisms of systemic inflammation following COVID-19 and any immune correlates of ongoing symptoms.

We examined a prospective cohort of individuals followed systematically post confirmed Immune profiles identified in COVID-19 were compared with subjects who had been infected with common cold coronaviruses (HCoV-NL63, O229E, OC43 or HKU1) and unexposed healthy donors.

The ADAPT study is a prospective cohort study of post-COVID-19 recovery established in April 2020 23 . 147 participants with confirmed SARS-CoV-2 infection were enrolled, the majority following testing in community based clinics run by St Vincent's Hospital Sydney, with some self-reffered long COVID care patients also also enrolled. Initial study follow-up was planned for 12 months post-COVID-19, but was recently extended to 2 years. Extensive clinical data and a biorepository was systematically collected prospectively. The aims of ADAPT are to evaluate a number of outcomes after COVID-19 relating to pathophysiology, immunology and clinical sequalae. Laboratory testing for SARS-CoV-2 was performed using nucleic acid detection from respiratory specimens with the EasyScreen™ Respiratory Detection kit All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21257759 doi: medRxiv preprint (Genetic Signatures, Sydney, Australia), and the EasyScreen™ SARS-CoV-2 Detection kit. Two ADAPT cohort sub-populations were defined based on initial severity of COVID-19 illness; 1.

patients managed in the community and 2. patients admitted to hospital for acute infection (including those requiring intensive care support for acute respiratory distress syndrome (ARDS). Patients were defined as 'long COVID' at 4-months based on the presence of any ≥ 1 of the following; fatigue, dyspnoea or chest pain 23 . These patients were gender and age (+/-10 years) matched with ADAPT participants without long COVID (Matched ADAPT controls) ( Table 1) . Samples for these analyses were collected at the 3-, 5-and 8-month assessments.

A further population of patients presenting to St Vincent's Hospital clinics for COVID-19 testing on the multiplex respiratory panel who were PCR positive for any of the 4 human common cold coronaviruses (HCoV-NL63, O229E, OC43 or HKU1) and PCR negative for SARS-CoV-2 were recruited into the ADAPT-C sub study and used as a comparator group.

The ADAPT study was approved by the St Vincent's Hospital Research Ethics Committee (2020/ETH00964) and is a registered trial (ACTRN12620000554965). ADAPT-C sub study was approved by the same committee (2020/ETH01429). All data were stored using REDCap 

Blood was collected for biomarker analysis (SST 8.5mLs x 1 (Serum) and EDTA 10mLs x 1 (Plasma)) and 36mLs was collected for PBMCs (ACD 9mLs x4). Phenotyping of PBMC was performed as described previously 25 . Briefly, cryopreserved PBMCs were thawed using RPMI (+L-glut) medium (ThermoFisher Scientific, USA) supplemented with Penicillin/Streptomycin 

Plasma ACE2 activity was measured using a validated, sensitive quenched fluorescent substrate-based assay as previously described 26 . Briefly, plasma (0.25 ml) was diluted into low-ionic-strength buffer (20 mmol/L Tris-HCl, pH 6.5) and added to 200 ml ANXSepharose 4

Fast-Flow resin (Amersham Biosciences, GE Healthcare, Uppsala, Sweden) that removed a previously characterized endogenous inhibitor of ACE2 activity. After binding and washing, the resulting eluate was assayed for ACE2 catalytic activity. Duplicate samples were incubated with the ACE2-specific quenched fluorescent substrate, with or without 100 mM ethylenediaminetetraacetic acid. The rate of substrate cleavage was determined by comparison to a standard curve of the free fluorophore, 4-amino-methoxycoumarin (MCA;

Sigma, MO, USA) and expressed as rmole of substrate cleaved/mL of plasma/min. The intraassay and inter-assay coefficient of variation was 5.6% and 11.8% respectively. Fig. 1 ). The newly generated FCS files were labelled according to control or patient group (long COVID or matched controls) and concatenated per group. Subsequently, 20, 000 events were taken from each grouped sample by downsampling. The two new FCS files corresponding to long COVID and matched controls were then concatenated for dimensionality reduction analysis using TriMap (40, 000 events in total). TriMap was conducted using the following parameters-to include the markers CD25, CD38, CCR7, CD19, IgD, CD45RA, PD-1, TIM-3, CD4, CD57, CD127, CD27, HLA-DR, CD8, CXCR5,GPR56 and Granzyme B, and using the following conditions: metric = euclidean, nearest neighbours = 15, and minimum distance = 0.5. Phenograph plugin was then used to determine clusters of phenotypically related cells. The same markers as TriMap and parameters k = 152 and Run ID = auto was used for analysis. Finally, ClusterExplorer plugin was used to identify the phenotype of the clusters generated by phenograph.

All column graphs are presented as medians with inter-quartile ranges. Wilcoxon paired t test was used to analyse statistical data employing Prism 9.0 (GraphicPad, La Jolla, CA, USA) software. For unpaired samples Mann-Whitney U test was used. RStudio version 1.2.1335 was used to generate correlograms utilizing corrplot package and Spearman's rank-order correlation coefficient with an adjusted FDR <0.05. p values <0.05 were considered significant (*<0.05, **<0.01, ***<0.001, and ****<0.0001).

In order to assess biomarkers associated with recovery from symptomatic SARS-CoV-2 infection; 28 analytes were analysed from serum of convalescent subjects with long COVID (LC) or asymptomatic matched controls (MC) at 5 months post-infection. Individuals that were PCR positive for prevalent common cold coronaviruses (HCoV) and sampled within the same time frame following infection (3-6months) and unexposed healthy donors sampled prior to December 2019, were used as comparator groups. Six pro-inflammatory analytes were highly elevated in the two COVID-19 convalescent ADAPT groups compared to control groups ( Fig.   1A ), while no difference was observed with the 22 other analytes (Supp. Fig. 2A&B ). Type I interferon-b (IFN-b) was 7.92-fold (median values shown in Supp. Fig 2C) and 7.39-fold higher in LC and MC compared to HCoV (both p<0.0001), and 7.32-and 6.83-fold higher compared to unexposed healthy controls (both p<0.0001, respectively). Type III interferon-lamdba1 (IFN-l1) was 2.44-fold and 3.24-fold higher in LC and MC compared to HCoV (both p<0.0001), and 2.42-and 3.21-fold higher compared to unexposed, (both p<0.0001, respectively). This was also the case for IL-8 (CXCL8) levels; LC=3.43-fold and MC=3.56-fold higher compared to Reduction of CXCL9 (MIG-1), CXCL10 (IP-10) and sTIM-3 were evident in both groups at 8 months. There were also decreases in the levels of some of the 22 analytes not significantly different to control groups at month 5 by month 8 (Supp. Fig. 2A&B ).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21257759 doi: medRxiv preprint

Plasma ACE2 activity levels have recently been shown to be elevated out to a median of 114 days following SARS-CoV-2 infection 27 , and we sought to investigate whether this was the case within the ADAPT longitudinal cohort at 3-, 5-and 8-months post-infection. At and no significant difference was observed when compared to levels at 3-and 5-months or when compared to HCoV. This indicated that increased plasma ACE2 activity is specific to SARS-CoV-2 infection and is not a common feature of other coronaviruses.

Immune responses to viral infections involve communication of multiple specialised cell populations through direct interactions, secreted cytokines and various mediators in a concerted effort to combat the infectious agent. To obtain a broader scope of systems-level interactions following convalescence, we generated correlation matrices from 29 analytes present in blood at 5 months post-infection (Fig. 3 ). This analysis revealed multiple positive correlations across a spectrum of 15 markers of inflammation and immune activation that include: IL-1b, , IL-33 (IL-1 family cytokines); IL-12p70, IFN-g, TNF-a (Type 1 (Th1) cytokines); IL-5, IL-6, IL-9, IL-13, TGF-b1 (Type 2 (Th2) cytokines); IFN-a2, IFN-l2/3 (interferons), GM-CSF, sCD25,and MCP-1 (CCL2), in the LC group most of which were not present in the asymptomatic MC group, where there was mostly no correlation or an inverse correlation between analytes (Fig. 3 A&B) . These correlations in the LC group included analytes that were All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; not significantly increased, revealing an apparent diffuse, potentially coordinated, low level up regulation of a spectrum of immune and inflammatory mediators in this group. At 8 months a similar diffuse inflammatory profile persisted for LC subjects (Fig. 3C) and was again not observed in MCs (Fig. 3D) . Notably among these correlations, IFN-b (rho=0. 38 populations remined absent, that is 1) CD127-GzmB-CCR7+CD45RA+CD27+ Naïve CD8+ T cells, 2) CD127-TIM-3 neg CCR7+CD45RA+CD27+ Naïve CD4+ T cells, and 3) CD38 low CD27-Naïve All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21257759 doi: medRxiv preprint IgD+ B cells (Fig. 5B ). These findings are indicative of ongoing inflammation through to 8 months in LC subjects. There was no reconstitution of these un-activated naïve T and B cell subsets even at 8 months post-infection in peripheral blood, however other naïve subsets that are more activated are present (Suppl. Fig 6) . Highly activated non-lymphoid cells 

Our study demonstrates several unique and important findings in relation to understanding long-term outcomes from COVID-19. Firstly, we show that several cytokines, mostly from interferon I and III classes, but also chemokines down stream of IFN-g, were highly elevated in people following resolution of active SARS-CoV-2 infection compared to controls and remained so up to 8 months after initial infection. This finding was observed largely irrespective of persistent symptoms. Secondly, we demonstrate similar findings in relation to elevation of plasma ACE2 levels at 5 months compared to controls, with some observed decrease by 8 months. Finally, and of most interest, we report an elevated diffuse inflammatory cytokine profile in symptomatic 'long COVID subjects' that is maintained at 8 months post-infection and is not observed in those with post-COVID-19 recovery. In addition, immune cell phenotyping reveals an absence of un-activated naïve T and B cell subsets in peripheral blood and an increase in cellular activation markers CD38 and HLA-DR that are highly expressed on myeloid cells from long COVID subjects at 8 months, suggesting maintenance of long-lasting inflammation in these individuals. Together these findings suggest that SARS-CoV-2 infection exerts a uniquely prolonged effect on aspects of both the All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ;  innate and adaptive immune systems, and that this may be driving the post COVID symptomology known as 'long COVID'.

Type I and III Interferons, namely IFN-b and IFN-l1 were highly elevated in our COVID-19 convalescent subjects compared to HCOV and unexposed subjects, and their levels decreased (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21257759 doi: medRxiv preprint and pulmonary fibrosis 43, 44 . Both chemokines have been implicated in symptomatic acute coronavirus infections, including COVID-19, where levels were higher in severe compared to asymptomatic subjects 45 , consistent with our data. Similarly, CXCL8 (IL-8) produced by lung epithelium and airway resident macrophages, has previously been shown to be released by lung cells after activation by spike proteins from SARS-CoV-1 46 . CXCL8 acts as a chemoattractant that facilitates migration of inflammatory T cells and neutrophils, that may contribute to alveolar damage 47, 48 . In contrast to CXCL9 and CXCL10, IL-8 levels persist at 8 months in subjects with long COVID and may play a role in sustaining the inflammatory milieu. Another membrane bound protein found to be 'shed' during COVID-19 is ACE2, which is also an important receptor for host cell entry 55 . Patel et al showed that shedding of ACE2 from the cell membrane resulted in increased plasma ACE2 activity levels in convalescent COVID-19 subjects 27 . Our data corroborates with this finding, where elevated plasma ACE2 activity occurred in COVID-19 infection regardless of symptom severity, at a higher level than HCoV and unexposed, persisted at 5 months, and decreased at 8 months in most subjects. It remains to be determined whether increased plasma ACE2 activity is associated with prolonged cardiac abnormalities following COVID-19 infection.

Finally, T cell activation via surrogate markers CD38 and HLA-DR, T cell exhaustion, together with an increase in B cell plasmablasts during severe COVID-19 has been reported 56-58 . We found no difference between activation levels as judged by cell surface expression of these All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our data does have some limitations. Firstly, although our long COVID 'cases' and controls were matched for two major characteristics (age and gender) it is possible that the differences observed reflect other key demographic or other factors between the groups. Secondly, although 7 of the 29 analytes were observed to be abnormally elevated, 22 of 29 were not (including key cytokines often implicated in chronic fatigue syndromes such as Pentraxin-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. A All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. 1-CD8+CD127+GzmB+CD57+CD38 mid HLA-DR mid 2-CD8+CD127+GzmB+CD57-CD38 low HLA-DR low 3-CD8+CD127+GzmB-CD57-CD38 low HLA-DR low 4-CD8+CD127-GzmB-CD57-CD38 low HLA-DR low 5-CD4+CD127+TIM-3 mid CD57+CD38 low HLA-DR mid 6-CD4+CD127+TIM-3 mid CD38 mid HLA-DR low 7-CD4+CD127-TIM-3 neg CD38 low HLA-DR low 8-CD4+CD127+TIM-3 low CD38 low HLA-DR low 1-CD127+TIM-3 mid CD38 low HLA-DR low 2-CD127-TIM-3 mid CD38 low HLA-DR mid 3-CD127+TIM-3 mid CD38 mid HLA-DR low 4-CD127-TIM-3 low CD38 low HLA-DR mid 5-CD127-TIM-3 neg CD38 low HLA-DR low 6-CD127+TIM-3 low CD38 mid HLA-DR low 7-CD127-TIM-3 low CD38 low HLA-DR low 8-CD127+TIM-3 low CD38 low HLA-DR mid All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 3, 2021. ; https://doi.org/10.1101/2021.06.01.21257759 doi: medRxiv preprint

Attributes and predictors of long COVID

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

The first 12 months of COVID-19: a timeline of immunological insights

Clinical and immunological features of severe and moderate coronavirus disease 2019

Cytokine release syndrome in severe COVID-19

A Novel Coronavirus from Patients with Pneumonia in China

Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome

Chronic COVID syndrome: Need for an appropriate medical terminology for long-COVID and COVID long-haulers

Rapid implementation of a cohort for the study of post-acute sequelae of SARS-CoV-2 infection/COVID-19. medRxiv

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

An overview on severe acute respiratory syndrome (SARS)

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes

Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Pathogenic potential of interferon alphabeta in acute influenza infection

Antitumour actions of interferons: implications for cancer therapy

IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function

Type III interferons disrupt the lung epithelial barrier upon viral recognition

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

CXCL10, CXCL11/CXCR3 axis for immune activation -A target for novel cancer therapy

CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features

Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands

Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China

Induction of IL-8 release in lung cells via activator protein-1 by recombinant baculovirus displaying severe acute respiratory syndrome-coronavirus spike proteins: identification of two functional regions

Chronic obstructive pulmonary disease

New endogenous CXC chemokine ligands as potential targets in lung emphysema

Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments

The authors thank the staff at the